KR100514963B1 - 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물 - Google Patents

4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물 Download PDF

Info

Publication number
KR100514963B1
KR100514963B1 KR10-1999-7001987A KR19997001987A KR100514963B1 KR 100514963 B1 KR100514963 B1 KR 100514963B1 KR 19997001987 A KR19997001987 A KR 19997001987A KR 100514963 B1 KR100514963 B1 KR 100514963B1
Authority
KR
South Korea
Prior art keywords
carbon atoms
alkyl
hydrogen
substituted
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-1999-7001987A
Other languages
English (en)
Korean (ko)
Other versions
KR20000068528A (ko
Inventor
노부유끼 하나무라
야스히데 호리우찌
료지 요시이
다까오 아오끼
미찌오 하라
Original Assignee
도레이 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도레이 가부시끼가이샤 filed Critical 도레이 가부시끼가이샤
Publication of KR20000068528A publication Critical patent/KR20000068528A/ko
Application granted granted Critical
Publication of KR100514963B1 publication Critical patent/KR100514963B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
KR10-1999-7001987A 1997-07-11 1998-07-10 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물 Expired - Lifetime KR100514963B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18695097 1997-07-11
JP97-186950 1997-07-11

Publications (2)

Publication Number Publication Date
KR20000068528A KR20000068528A (ko) 2000-11-25
KR100514963B1 true KR100514963B1 (ko) 2005-09-15

Family

ID=16197570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7001987A Expired - Lifetime KR100514963B1 (ko) 1997-07-11 1998-07-10 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물

Country Status (15)

Country Link
US (1) US6372755B2 (enExample)
EP (1) EP0948965B1 (enExample)
JP (3) JP3617055B2 (enExample)
KR (1) KR100514963B1 (enExample)
CN (1) CN100379419C (enExample)
AT (1) ATE268178T1 (enExample)
AU (1) AU740404B2 (enExample)
CA (1) CA2265767C (enExample)
DE (1) DE69824277T2 (enExample)
DK (1) DK0948965T3 (enExample)
ES (1) ES2217563T3 (enExample)
NO (1) NO318831B1 (enExample)
PT (1) PT948965E (enExample)
TW (1) TWI285644B (enExample)
WO (1) WO1999002158A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
SG90259A1 (en) * 2000-08-17 2002-07-23 Control Ox Oy Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections
JP4880813B2 (ja) * 2000-10-26 2012-02-22 第一三共株式会社 外用消炎鎮痛剤組成物
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
JP4963670B2 (ja) * 2004-04-07 2012-06-27 レスベラトロル パートナーズ， エルエルシー 栄養補助サプリメントおよびそれを処理する方法
US8288362B2 (en) 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
WO2005110439A2 (en) * 2004-05-07 2005-11-24 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
US20080096967A1 (en) * 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
TWI286941B (en) * 2005-07-27 2007-09-21 Anagen Therapeutics Inc Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof
PL2151241T3 (pl) * 2007-04-26 2012-08-31 Toray Industries Trwały stały preparat zawierający pochodną 4,5-epoksymorfinanową
ES2648037T3 (es) * 2007-05-21 2017-12-28 Toray Industries, Inc. Preparación oral que comprende un ácido orgánico específico y método para mejorar la propiedad de disolución y la estabilidad química de la preparación oral
CN101658489B (zh) * 2008-08-27 2011-11-23 海南四环心脑血管药物研究院有限公司 一种盐酸纳美芬注射液及其制备方法
BRPI0920599B1 (pt) * 2008-10-24 2021-10-19 Toray Industries, Inc. Comprimido estável contendo um derivado de 4,5-epoximorfinano
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
AU2010255747B2 (en) * 2009-06-04 2014-03-13 Alk-Abello A/S Stabilised composition comprising at least one adrenergic compound
ES2933198T3 (es) 2010-10-21 2023-02-02 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para usar
JP5750278B2 (ja) * 2011-02-28 2015-07-15 東洋カプセル株式会社 カンデサルタンシレキセチルのカプセル充填用組成物
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
JP6247118B2 (ja) * 2014-03-05 2017-12-13 東海カプセル株式会社 カプセル充填組成物
CA2980097C (en) 2015-03-19 2019-10-29 Daiichi Sankyo Company, Limited Solid preparation containing colorant
EP3272345B1 (en) * 2015-03-19 2019-10-16 Daiichi Sankyo Company, Limited Solid preparation containing antioxidant agent
JP5918894B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN119157840A (zh) 2016-07-29 2024-12-20 东丽株式会社 光稳定性提高的固体制剂
JP6131379B1 (ja) * 2016-12-28 2017-05-17 森下仁丹株式会社 ４，５−エポキシモルヒナン誘導体含有製剤
JP7153197B2 (ja) * 2017-03-31 2022-10-14 東レ株式会社 ナルフラフィンを含有する錠剤化された医薬組成物
AU2019229892B2 (en) 2018-03-08 2025-01-30 University Of Kansas Treatment of demyelinating diseases
KR102849723B1 (ko) 2018-07-30 2025-08-22 다이이찌 산쿄 가부시키가이샤 안정화제를 함유하는 의약품의 고형 제제
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
WO2020205735A1 (en) 2019-03-29 2020-10-08 Humanwell Pharmaceutical US Novel morphinans useful for treating medical disorders
EP4062973A4 (en) * 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2765694B2 (ja) * 1988-01-29 1998-06-18 日清バーディシェ株式会社 酸化感受性化合物の安定な組成物
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
ES2121988T3 (es) * 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
NZ268969A (en) * 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
DE29719704U1 (de) 1997-02-14 1998-01-22 Gödecke AG, 10587 Berlin Stabile Zubereitungen von Naloxonhydrochlorid

Also Published As

Publication number Publication date
JP3617055B2 (ja) 2005-02-02
CN100379419C (zh) 2008-04-09
DE69824277D1 (de) 2004-07-08
ES2217563T3 (es) 2004-11-01
JP3743449B2 (ja) 2006-02-08
CN1237106A (zh) 1999-12-01
NO318831B1 (no) 2005-05-09
AU740404B2 (en) 2001-11-01
CA2265767C (en) 2007-12-04
DK0948965T3 (da) 2004-07-05
US20010004637A1 (en) 2001-06-21
CA2265767A1 (en) 1999-01-21
ATE268178T1 (de) 2004-06-15
EP0948965B1 (en) 2004-06-02
JP2005247866A (ja) 2005-09-15
PT948965E (pt) 2004-08-31
NO991152D0 (no) 1999-03-10
DE69824277T2 (de) 2004-09-23
US6372755B2 (en) 2002-04-16
EP0948965A4 (en) 2002-10-16
KR20000068528A (ko) 2000-11-25
NO991152L (no) 1999-05-10
JP2005002123A (ja) 2005-01-06
TWI285644B (en) 2007-08-21
AU8128298A (en) 1999-02-08
WO1999002158A1 (fr) 1999-01-21
EP0948965A1 (en) 1999-10-13
JP4311369B2 (ja) 2009-08-12

Similar Documents

Publication Publication Date Title
KR100514963B1 (ko) 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물
JPWO1999002158A1 (ja) ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物
JP2005002123A5 (enExample)
RU2767410C2 (ru) Новые композиции и способы
EP0754030B1 (en) Method for stabilizing duocarmycin derivatives
EP0389995A2 (en) Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
WO2009107983A2 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
IE51637B1 (en) Pharmaceutical preparation
JPWO2008023807A1 (ja) 安定化された医薬組成物
WO1998041210A1 (en) Sustained-release prostaglandin i derivative preparation
KR100440354B1 (ko) 티아가빈염산염함유약학적조성물및그제조방법
CN1046516C (zh) 化合物dx－52－1的稳定方法和其冻干组合物
BR112015000688B1 (pt) Composição aquosa, composição farmacêutica líquida, método para a produção de uma composição aquosa, uso de um excipiente, recipiente e kit
US4968673A (en) Use of a thromboxane receptor antagonist in renal diseases and dysfunction
EP0055593B1 (en) Compositions comprising e-prostaglandins
JPH0873361A (ja) 抗腫瘍薬物の用時調合型セット製剤
KR900002745B1 (ko) 안정 주사용 진토제 조성물의 제조방법
KR100581543B1 (ko) 프로스타글란딘i 유도체 서방성제제
US4882356A (en) Stable injectable antiemetic compositions
KR100384346B1 (ko) 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물
JP3178726B2 (ja) 抗菌剤組成物
JP3148263B2 (ja) 抗菌性組成物
WO2025165852A1 (en) Liquid formulations of lurbinectedin
JPH08231398A (ja) 凍結乾燥製剤
WO2018031427A1 (en) Pharmaceutical formulations and their use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990310

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030403

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041222

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20050715

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20050907

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20050908

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20080825

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20090824

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20100825

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110811

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20120821

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20120821

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20130822

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20130822

Start annual number: 9

End annual number: 9

PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20130913

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20140825

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20140825

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150819

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150819

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20160818

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20170822

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20170822

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20180816

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20180816

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20190819

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20190819

Start annual number: 15

End annual number: 15

PC1801 Expiration of term